ALKSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Alkermes plc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$42.97+1.75 (+4.25%)
Close on Oct 19, 2026
- Market cap
- $7.45B
- P/E (TTM)
- 113.1
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2010 to 2025
Gross margin
86.7%+3.9 pts over 5 years
Operating margin
17.2%+28.0 pts over 5 years
Net margin
16.4%+27.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -5.2% | +9.9% | +7.3% | +8.9% | |
| Gross profit | -2.5% | +12.7% | +8.3% | +10.1% | |
| Operating income | -39.6% | – | – | – | |
| Net income | -34.2% | – | – | – | |
| EPS, diluted | -34.1% | – | – | – | |
| Free cash flow | +18.4% | – | +63.9% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -16.5% | -10.3% | 14.7% | |
| Return on assets | -11.6% | -5.9% | 10.6% | |
| Current ratio | 3.73 | 2.53 | 3.55 | |
| Debt to equity | 0.23 | 0.26 | 0.00 | |
| Net debt to EBITDA | -0.85× | -0.07× | -1.38× | |
| Interest coverage | -14.0× | -13.0× | 20.7× | |
| Inventory turnover | 2.6× | 1.6× | 1.0× | |
| Capex to revenue | 5.9% | 4.1% | 2.7% | |
| Diluted shares | 151M | 159M | 169M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Alkermes generated $1.48B from operations and spent $388.51M on capital expenditure, dividends and share buybacks. 48% of that went back into the business.
Generated
$1.48B
Used
$388.51M
Capital expenditure$188.23M48%Dividends$00%Share buybacks$200.28M52%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin16.4%
×Asset turnover0.65×
×Equity multiplier1.38×
=Return on equity, FY202514.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 16.4% | 0.65× | 1.38× | 14.7% |
| FY2024 | 23.6% | 0.74× | 1.57× | 27.5% |
| FY2023 | 21.4% | 0.81× | 1.83× | 31.7% |
| FY2022 | -14.2% | 0.56× | 1.85× | -14.7% |
| FY2021 | -4.1% | 0.59× | 1.82× | -4.4% |
| FY2020 | -10.7% | 0.55× | 1.74× | -10.3% |
| FY2019 | -16.8% | 0.65× | 1.61× | -17.4% |
| FY2018 | -12.7% | 0.60× | 1.53× | -11.7% |
| FY2017 | -17.5% | 0.51× | 1.46× | -13.1% |
| FY2016 | -28.0% | 0.42× | 1.42× | -16.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$241.66M
- Cash generatingOperating cash flow above zero$520.75M
- Return on assets improvedROA up on the prior year17.2% → 11.8%
- Earnings backed by cashOperating cash flow above net income$520.75M vs $241.66M
- Less leverageLong-term debt to assets fell– → 0.0%
- Better liquidityCurrent ratio rose3.04 → 3.55
- No dilutionShare count did not rise169M → 169M
- Gross margin improvedGross margin up on the prior year84.25% → 86.69%
- More efficientAsset turnover rose0.73 → 0.72